According to our estimates, just under 50 companies accounted for more than 85% of all orthopedic revenue in 2023.

Orthopedics’ Top Tier to Expand in 2024

According to our estimates, just under 50 companies accounted for more than 85% of all orthopedic revenue in 2023.

The Numbers
Stay up to date on the orthopedic market's 4Q performance in 2023 as we update this post with company sales data and industry developments.

Orthopedic Volume Trends Remained Strong in Fourth Quarter

Stay up to date on the orthopedic market’s 4Q performance in 2023 as we update this post with company sales data and industry developments.

Funding announcements came from familiar names and supported well-backed markets like spine and enabling technology.

10 Orthopedic Companies Close New Funding Rounds in 1Q24

Funding announcements came from familiar names and supported well-backed markets like spine and enabling technology.

Orthoflash®
Using a patented Z shape, the devices are designed to allow microcushioning to reduce subsidence and adjacent level stresses.
SpinePoint Medical Previews Low-Stiffness Cervical Interbody Cage

Using a patented Z shape, the devices are designed to allow microcushioning to reduce subsidence and adjacent level stresses.

,
GMReis Miro
GMReis Granted US Patent on MIRO Guide for MICA Procedure

GMReis’ device will help surgeons more accurately perform its MIS Foot – MICA procedure using the MIRO single-use guide to control rotation correction .

,
Centinel Spine prodisc C Vivo and prodisc C SK
Centinel Spine Exceeds 5,000 US prodisc Procedures

The cervical business grew ~90% in 2023 as additional surgeons gained access to the new prodisc C Vivo and prodisc C SK Match-the-Disc system.

,
16 Bit offers Rho, AI-enabled software aimed at improving a known care gap in osteoporosis screening.
FDA De Novo for 16 Bit Bone Density Screening Tool

16 Bit offers Rho, AI-enabled software aimed at improving a known care gap in osteoporosis screening.

,
Lipogems ARISE I U.S. FDA IDE study
Enrollment Complete in Lipogems ARISE I Study

Lipogems completed enrollment in the ARISE I FDA IDE study examining MicroFat vs. corticosteriod injection for the treatment of knee OA.

,
Competitive Landscape
Industry Voices

Contact Us

0